Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PRNP | P04156 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26632797 | 0.89 | NR4A2 (0.45) | SMN1; SMN2LMNAALDH1A1MAPTGLA | |
| SCHEMBL19643620 | 0.83 | GAK (0.44) | GAK | |
| SCHEMBL4490029 | 0.83 | SLC22A12 (0.47) | SMN1; SMN2LMNACYP1A2HTTGAK | |
| SCHEMBL28544908 | 0.83 | ESR2 (0.47) | SMN1; SMN2LMNAALDH1A1MAPTGLA | |
| SCHEMBL3551410 | 0.81 | HTR1A (0.46) | LMNAGAK | |
| SCHEMBL3576735 | 0.80 | KDR (0.40) | SMN1; SMN2MAPTCYP1A2HTT | |
| SCHEMBL2185158 | 0.80 | PDE4A (0.34) | SMN1; SMN2LMNAPDE4APDE4CPDE4D | |
| SCHEMBL14999154 | 0.79 | SRC (0.39) | SMN1; SMN2 | |
| SCHEMBL17027082 | 0.78 | NT5E (0.43) | SMN1; SMN2LMNAALDH1A1MAPTHPGD | |
| SCHEMBL371799 | 0.78 | PDGFRB (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111635358-B | Preparation method of hydroxychloroquine | 北京成宇化工有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-111635358-A | Preparation method of hydroxychloroquine | 北京成宇化工有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-1836201-B1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH INC (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SMN1; SMN2 2913/4885LMNA 2663/4885ALDH1A1 4197/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SMN1; SMN2 2913/4885LMNA 2663/4885ALDH1A1 4197/4885 |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | SMN1; SMN2 2913/4885LMNA 2663/4885ALDH1A1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.